MedPath

GPCR Therapeutics, Inc.

GPCR Therapeutics, Inc. logo
🇰🇷South Korea
Ownership
Holding
Established
2013-01-01
Employees
11
Market Cap
-
Website
http://www.gpcr.co.kr

Clinical Trials

5

Active:1
Completed:4

Trial Phases

2 Phases

Phase 1:1
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
4 (80.0%)
Phase 1
1 (20.0%)

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Phase 2
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
First Posted Date
2022-09-30
Last Posted Date
2025-06-22
Lead Sponsor
GPCR Therapeutics, Inc.
Target Recruit Count
40
Registration Number
NCT05561751
Locations
🇺🇸

University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, United States

🇺🇸

University of Florida (UF) - Shands Cancer Center, Gainesville, Florida, United States

🇺🇸

Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States

and more 7 locations

PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

Phase 2
Completed
Conditions
Non-Hodgkin Lymphoma
Multiple Myeloma
Hodgkin Disease
Interventions
Drug: TG-0054 combined with G-CSF
First Posted Date
2014-04-04
Last Posted Date
2021-04-19
Lead Sponsor
GPCR Therapeutics, Inc.
Target Recruit Count
12
Registration Number
NCT02104427
Locations
🇺🇸

Stony Brook University Hospital, Stony Brook, New York, United States

🇺🇸

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

Phase 2
Completed
Conditions
Multiple Myeloma
Hodgkin's Disease
Non-hodgkin's Lymphoma
Interventions
First Posted Date
2011-10-24
Last Posted Date
2021-04-19
Lead Sponsor
GPCR Therapeutics, Inc.
Target Recruit Count
12
Registration Number
NCT01458288
Locations
🇺🇸

Stony Brook University Hospital, Stony Brook, New York, United States

Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

Phase 2
Completed
Conditions
Multiple Myeloma
Non-Hodgkin Lymphoma
Hodgkin Disease
Interventions
Drug: TG-0054 (2.24 mg/kg)
Drug: TG-0054 (3.14 mg/kg)
First Posted Date
2009-11-25
Last Posted Date
2021-05-11
Lead Sponsor
GPCR Therapeutics, Inc.
Target Recruit Count
19
Registration Number
NCT01018979
Locations
🇨🇳

Chang-Gung Memorial Hospital Chiayi, Chiayi, Taiwan

🇨🇳

Buddist Tzu Chi General Hospital, Hualien, Taiwan

🇨🇳

Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

and more 3 locations

Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
First Posted Date
2009-01-14
Last Posted Date
2021-08-04
Lead Sponsor
GPCR Therapeutics, Inc.
Target Recruit Count
64
Registration Number
NCT00822341
Locations
🇺🇸

PAREXEL Clinical Pharmacology Research Unit Harbor Hospital Center, Baltimore, Maryland, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.